Increased expression of MDM2, cyclin D1, and p27Kip1 in carcinogen-induced rat mammary tumors

Journal of Cellular Biochemistry

Volumn 95, Issue 5, 2005, Pages 875-884

  Murray, Stephen A ^a   Yang, Shi ^a   Demicco, Elizabeth ^a   Ying, Haoqiang ^a   Sherr, David H ^b   Hafer, Laurie J ^a   Rogers, Adrianne E ^a   Sonenshein, Gail E ^a   Xiao, Zhi Xiong Jim ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Animal models; Breast cancer; Carcinogen; DMBA; MDM2; p27Kip1

Indexed keywords

7,12 DIMETHYLBENZ[A]ANTHRACENE; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; POLYCYCLIC AROMATIC HYDROCARBON; PROTEIN KINASE B; PROTEIN MDM2; PROTEIN P53;

ANIMAL CELL; ARTICLE; BREAST TUMOR; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOPLASM; DOSE TIME EFFECT RELATION; FEMALE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; NONHUMAN; PHOSPHORYLATION; POLLUTANT; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ANIMALS; BLOTTING, WESTERN; CARCINOGENS; CELL CYCLE PROTEINS; CYCLIN D1; CYCLIN-DEPENDENT KINASE INHIBITOR P27; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; MAMMARY GLANDS, ANIMAL; MAMMARY NEOPLASMS, EXPERIMENTAL; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; RATS; RATS, SPRAGUE-DAWLEY; RETINOBLASTOMA PROTEIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

ANIMALIA; MINK CELL FOCUS-FORMING VIRUS; MURINAE; RODENTIA;

EID: 26444540439     PISSN: 07302312     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcb.20414     Document Type: Article

References (64)

1. Adams PD. 2001. Regulation of the retinoblastoma tumor suppressor protein by cyclin/cdks. Biochim Biophys Acta 1471:M123-M133.
2. Barak Y, Juven T, Haffner R, Oren M. 1993. MDM2 expression is induced by wild type p53 activity. EMBO J 12:461-468.
3. Barnes DM, Gillett CE. 1998. Cyclin D1 in breast cancer. Breast Cancer Res Treat 52:1-15.
4. Bartkova J, Lukas J, Muller H, Lutzhoft D, Strauss M, Bartek J. 1994. Cyclin D1 protein expression and function in human breast cancer. Int J Cancer 57:353-361.
5. Blain SW, Montalvo E, Massague J. 1997. Differential interaction of the cyclin-dependent kinase (Cdk) inhibitor p27Kip1 with cyclin A-Cdk2 and cyclin D2-Cdk4. J Biol Chem 272:25863-25872.
6. Blain SW, Scher HI, Cordon-Cardo C, Koff A. 2003. p27 as a target for cancer therapeutics. Cancer Cell 3:111-115.
7. Buckley MF, Sweeney KJE, Hamilton JA, Sini RL, Manning DL, Nicholson RI, deFazio A, Watts CKW, Musgrove E, Sutherland RL. 1993. Expression and amplification of cyclin genes in human breast cancer. Oncogene 8:2127-2133.
8. Carneiro C, Jiao MS, Hu M, Shaffer D, Park M, Pandolfi PP, Cordon-Cardo C, Koff A. 2003. p27 deficiency desensitizes Rb-/- cells to signals that trigger apoptosis during pituitary tumor development. Oncogene 22:361-369.
9. Cheng M, Olivier P, Diehl JA, Fero M, Roussel MF, Roberts JM, Sherr CJ. 1999. The p21(Cip1) and p27(Kip1) CDK 'inhibitors' are essential activators of cyclin D-dependent kinases in murine fibroblasts. Embo J 18:1571-1583.
10. Ciaparrone M, Yamamoto H, Yao Y, Sgambato A, Cattoretti G, Tomita N, Monden T, Rotterdam H, Weinstein IB. 1998. Localization and expression of p27KIP1 in multistage colorectal carcinogenesis. Cancer Res 58:114-122.
11. Eymin B, Haugg M, Droin N, Sordet O, Dimanche-Boitrel MT, Solary E. 1999. p27Kip1 induces drug resistance by preventing apoptosis upstream of cytochrome c release and procaspase-3 activation in leukemic cells. Oncogene 18:1411-1418.
12. Fang S, Jensen JP, Ludwig RL, Vousden KH, Weissman AM. 2000. MDM2 is a RING finger-dependent ubiquitin protein ligase for itself and p53. J Biol Chem 275:8945-8951.
13. Fredersdorf S, Burns J, Milne AM, Packham G, Fallis L, Gillett CE, Royds JA, Peston D, Hall PA, Hanby AM, Barnes DM, Shousha S, O'Hare MJ, Lu X. 1997. High level expression of p27(kip1) and cyclin D1 in some human breast cancer cells: Inverse correlation between the expression of p27(kip1) and degree of malignancy in human breast and colorectal cancers. Proc Natl Acad Sci USA 94:6380-6385.
14. Gammon MD, Santella RM, Neugut AI, Eng SM, Teitelbaum SL, Paykin A, Levin B, Terry MB, Young TL, Wang LW, Wang Q, Britton JA, Wolff MS, Stellman SD, Hatch M, Kabat GC, Senie R, Garbowski G, Maffeo C, Montalvan P, Berkowitz G, Kemeny M, Citron M, Schnabel F, Schuss A, Hajdu S, Vinceguerra V. 2002. Environmental toxins and breast cancer on Long Island. I. Polycyclic aromatic hydrocarbon DNA adducts. Cancer Epidemiol Biomarkers Prev 11:677-685.
15. Gillett C, Fantl V, Smith R, Fisher C, Bartek J, Dickson C, Barnes D, Peters G. 1994. Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res 54:1812-1817.
16. Gillett C, Smith P, Gregory W, Richards M, Millis R, Peters G, Barnes D. 1996. Cyclin D1 and prognosis in human breast cancer. Int J Cancer 69:92-99.
17. Gu L, Ying H, Zheng H, Murray SA, Xiao ZX. 2003. The MDM2 RING finger is required for cell cycle-dependent regulation of its protein expression. FEBS Lett 544:218-222.
18. Han EK, Begemann M, Sgambato A, Soh JW, Doki Y, Xing WQ, Liu W, Weinstein IB. 1996. Increased expression of cyclin D1 in a murine mammary epithelial cell line induces p27kip1, inhibits growth, and enhances apoptosis. Cell Growth Differ 7:699-710.
19. Haupt Y, Maya R, Kazaz A, Oren M. 1997. MDM2 promotes the rapid degradation of p53. Nature 387:296-299.
20. Hiromura K, Pippin JW, Fero ML, Roberts JM, Shankland SJ. 1999. Modulation of apoptosis by the cyclin-dependent kinase inhibitor p27(Kip1). J Clin Invest 103:597-604.
21. Honda R, Yasuda H. 2000. Activity of MDM2, a ubiquitin ligase, toward p53 or itself is dependent on the RING finger domain of the ligase. Oncogene 19:1473-1476.
22. Honda R, Tanaka H, Yasuda H. 1997. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett 420:25-27.
23. Jang TJ, Rang MS, Kim H, Kim DH, Lee JI, Kim JR. 2000. Increased expression of cyclin D1, cyclin E and p21(Cip1) associated with decreased expression of p27(Kip1) in chemically induced rat mammary carcinogenesis. Jpn J Cancer Res 91:1222-1232.
24. Jiang HY, Petrovas C, Sonenshein GE. 2002. RelB-p50 NF-kappa B complexes are selectively induced by cytomegalovirus immediate-early protein 1: Differential regulation of Bcl-x(L) promoter activity by NF-kappa B family members. J Virol 76:5737-5747.
25. Kavanagh KT, Hafer LJ, Kim DW, Mann KK, Sherr DH, Rogers AE, Sonenshein GE. 2001. Green tea extracts decrease carcinogen-induced mammary tumor burden in rats and rate of breast cancer cell proliferation in culture. J Cell Biochem 82:387-398.
26. Kito K, Kihana T, Sugita A, Murao S, Akehi S, Sato M, Tachibana M, Kimura S, Ueda N. 1996. Incidence of p53 and Ha-ras gene mutations in chemically induced rat mammary carcinomas. Mol Carcinog 17:78-83.
27. Kubbutat MH, Jones SN, Vousden KH. 1997. Regulation of p53 stability by MDM2. Nature 387:299-303.
28. LaBaer J, Garrett MD, Stevenson LF, Slingerland JM, Sandhu C, Chou HS, Fattaey A, Harlow E. 1997. New functional activities for the p21 family of CDK inhibitors. Genes Dev 11:847-862.
29. Levine AJ. 1997. p53, the cellular gatekeeper for growth and division. Cell 88:323-331.
30. Li D, Wang M, Firozi PF, Chang P, Zhang W, Baer-Dubowska W, Moorthy B, Vulimiri SV, Goth-Goldstein R, Weyand EH, DiGiovanni J. 2002. Characterization of a major aromatic DNA adduct detected in human breast tissues. Environ Mol Mutagen 39:193-200.
31. Liang J, Zubovitz J, Petrocelli T, Kotchetkov R, Connor MK, Han K, Lee JH, Ciarallo S, Catzavelos C, Beniston R, Franssen E, Slingerland JM. 2002. PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G, arrest. Nat Med 8:1153-1160.
32. Lloyd RV, Jin L, Qian X, Kulig E. 1997. Aberrant p27kip1 expression in endocrine and other tumors. Am J Pathol 150:401-407.
33. Lloyd RV, Erickson LA, Jin L, Kulig E, Qian X, Cheville JC, Scheithauer BW. 1999. p27kip1: A multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers. Am J Pathol 154:313-323.
34. Loda M, Cukor B, Tam SW, Lavin P, Fiorentino M, Draetta GF, Jessup JM, Pagano M. 1997. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med 3:231-234.
35. Lundgren K, Luna RM, McNeill YB, Emerick EP, Spencer B, Barfield CR, Lozano G, Rosenberg MP, Finlay CA. 1997. Targeted expression of MDM2 uncouples S phase from mitosis and inhibits mammary gland development independent of p53. Genes Dev 11:714-725.
36. Marchetti A, Buttitta F, Girlando S, Dalla Palma P, Pellegrini S, Fina P, Doglioni C, Bevilacqua G, Barbareschi M. 1995. MDM2 gene alterations and MDM2 protein expression in breast carcinomas. J Pathol 175:31-38.
37. Martin K, Touche D, Hagemeier C, Sorensen TS, La-Thangue NB, Kouzarides T. 1995. Stimulation of E2F1/DPI transcriptional activity by MDM2 oncoprotein. Nature 375:691-694.
38. McCann AH, Kirley A, Carney DN, Corbally N, Magee HM, Keating G, Dervan PA. 1995. Amplification of the MDM2 gene in human breast cancer and its association with MDM2 and p53 protein status. Br Cancer 71:981-985.
39. Momand J, Jung D, Wilczynski S, Niland J. 1998. The MDM2 gene amplification database. Nucleic Acids Res 26:3453-3459.
40. Ophascharoensuk V, Fero ML, Hughes J, Roberts JM, Shankland SJ. 1998. The cyclin-dependent kinase inhibitor p27Kip1 safeguards against inflammatory injury. Nat Med 4:575-580.
41. Park DS, Levine B, Ferrari G, Greene LA. 1997. Cyclin dependent kinase inhibitors and dominant negative cyclin dependent kinase 4 and 6 promote survival of NGF-deprived sympathetic neurons. J Neurosci 17:8975-8983.
42. Park MS, Rosai J, Nguyen HT, Capodieci P, Cordon-Cardo C, Koff A. 1999, p27 and Rb are on overlapping pathways suppressing tumorigenesis in mice. Proc Natl Acad Sci USA 96:6382-6387.
43. Quesnel B, Preudhomme C, Fournier J, Fenaux P, Peyrat JP. 1994. MDM2 gene amplification in human breast cancer. Eur J Cancer 30A:982-984.
44. Rogers AE, Hafer LJ, Iskander YS, Yang S. 1998. Black tea and mammary gland carcinogenesis by 7,12-dimethylbenz(α)anthracene in rats fed control or high fat diets. Carcinogenesis 19:1269-1273.
45. Rogers AE, Sullivan LM, Hafer LJ. 1999, Dietary fat, body weight, and cancer: Contributions of studies in rodents to understanding these cancer risk factors in humans. Toxicol Sci 52:66-71.
46. Rundle A, Tang D, Hibshoosh H, Estabrook A, Schnabel F, Cao W, Grumet S, Perera FP. 2000. The relationship between genetic damage from polycyclic aromatic hydrocarbons in breast tissue and breast cancer. Carcinogenesis 21:1281-1289.
47. Rundle A, Tang D, Hibshoosh H, Schnabel F, Kelly A, Levine R, Zhou J, Link B, Perera F. 2002. Molecular epidemiologic studies of polycyclic aromatic hydrocarbon-DNA adducts and breast cancer. Environ Mol Mutagen 39:201-207.
48. Russo J, Russo IH, 1987. Biological and molecular basis of mammary carcinogenesis. Lab Invest 587:112-137.
49. Russo IH, Russo J. 1996. Mammary gland neoplasia in long-term rodent studies. Environ Health Perspe 104:938-967.
50. Sgambato A, Han EK, Zhang YJ, Moon RC, Santella RM, Weinstein IB. 1995. Deregulated expression of cyclin D1 and other cell cycle-related genes in carcinogen-induced rat mammary tumors. Carcinogenesis 16:2193-2198.
51. Sherr CJ. 1996. Cancer cell cycles. Science 274:1672-1677,
52. Shin I, Yakes FM, Rojo F, Shin NY, Bakin AV, Baselga J, Arteaga CL. 2002. PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization. Nat Med 8:1145-1152.
53. Sicinski P, Donaher JL, Parker SB, Li T, Fazeli A, Gardner H, Haslam SZ, Bronson RT, Elledge SJ, Weinberg RA. 1995. Cyclin D1 provides a link between development and oncogenesis in the retina and breast. Cell 82:621-630.
54. Singh SP, Lipman J, Goldman H, Ellis FH, Jr., Aizenman L, Cangi MG, Signoretti S, Chiaur DS, Pagano M, Loda M. 1998. Loss or altered subcellular localization of p27 in Barrett's associated adenocarcinoma. Cancer Res 58:1730-1735.
55. Slingerland J, Pagano M. 2000. Regulation of the cdk inhibitor p27 and its deregulation in cancer. J Cell Physiol 183:10-17.
56. St Croix B, Kerbel RS. 1997. Cell adhesion and drug resistance in cancer. Curr Opin Oncol 9:549-556.
57. St Croix B, Florenes VA, Rak JW, Flanagan M, Bhattacharya N, Slingerland JM, Kerbel RS, 1996. Impact of the cyclin-dependent kinase inhibitor p27Kip1 on resistance of tumor cells to anticancer agents. Nat Med 2:1204-1210.
58. Sun P, Dong P, Dai K, Hannon GJ, Beach D. 1998. p53-independent role of MDM2 in TGF-beta1 resistance. Science 282:2270-2272.
59. Viglietto G, Motti ML, Bruni P, Melillo RM, D'Alessio A, Califano D, Vinci F, Chiappetta G, Tsichlis P, Bellacosa A, Fusco A, Santoro M. 2002. Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) by PKB/Akt-mediated phosphorylation in breast cancer. Nat Med 8:1136-1144.
60. Vogelstein B, Lane D, Levine AJ. 2000. Surfing the p53 network. Nature 408:307-310.
61. Wang T, Cardiff R, Zukerberg L, Lees E, Arnold A, Schmidt E. 1994. Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature 369:669-671.
62. Weinstat-Saslow D, Merino MJ, Manrow RE, Lawrence JA, Bluth RF, Wittenbel KD, Simpson JF, Page DL, Steeg PS. 1995. Overexpression of cyclin D mRNA distinguishes invasive and in situ breast carcinomas from non-malignant lesions. Nature Med 1:1257-1260.
63. Xiao ZX, Chen J, Levine A, Modjtahedi N, Xing J, Sellers W, Livingston DM. 1995. Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature 375:694-698.
64. Yang W, Shen J, Wu M, Arsura M, FitzGerald M, Suldan Z, Kim DW, Hofmann CS, Pianetti S, Romieu-Mourez R, Freedman LP, Sonenshein GE. 2001. Repression of transcription of the p27(Kip1) cyclin-dependent kinase inhibitor gene by c-Myc, Oncogene 20:1688-16702.